Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 2nd Committee on Drugs Recommends Approval of Aredia
October 25, 2004
- BULLETIN
October 25, 2004
- REGULATORY NEWS IN BRIEF
October 25, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 25, 2004
- 3Qtrs Business Results
October 25, 2004
- Business Forecast
October 25, 2004
- Business Forecast
October 25, 2004
- WORLD NEWS IN BRIEF
October 25, 2004
- 55th WMA General Assembly
October 25, 2004
- Necessary to Further Open the Way to Mixed Medical Care: Health Minister Otsuji
October 25, 2004
- Ministries to Cooperate to Develop Nanotech in Healthcare Field
October 25, 2004
- NER PRODUCTS
October 25, 2004
- Continue to Grow Above Market Level: Mr Banchi of Boehringer Ingelheim
October 25, 2004
- Council Insists on Lifting of Ban on "Mixed Medical Care"
October 25, 2004
- Roche Eager to Strengthen Presence in Japan: Mr Noguchi
October 25, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 25, 2004
- Creating a New Kind of Drug Distributor: Mediceo Holdings
October 25, 2004
- BULLETIN
October 25, 2004
- Quintiles Japan Eager to Conduct Joint Clinical Trials in Japan, Asia
October 25, 2004
- BULLETIN
October 25, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…